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Abstract 
Background: Chemoresistance hinders curative cancer chemotherapy in osteosarcoma (OS), resulting in only an 
approximately 20 % survival rate in patients with metastatic disease at diagnosis. Identifying the mechanisms respon-
sible for regulating chemotherapy resistance is crucial for improving OS treatment.
Methods: This study was performed in two human OS cell lines (the multi-chemosensitive OS cell line G-292 and the 
multi-chemoresistant OS cell line SJSA-1). The levels of miR-20a-5p and KIF26B mRNA expression were determined by 
quantitative real-time PCR. KIF26B protein levels were determined by western blot analysis. Cell viability was assessed 
by MTT assay. Apoptosis was evaluated by flow cytometry.
Results: We found that miR-20a-5p was more highly expressed in G-292 cells than in SJSA-1 cells. Forced expression 
of miR-20a-5p counteracted OS cell chemoresistance in both cell culture and tumor xenografts in nude mice. One of 
miR-20a-5p’s targets, kinesin family member 26B (KIF26B), was found to mediate the miR-20a-5p-induced reduction in 
OS chemoresistance by modulating the activities of the MAPK/ERK and cAMP/PKA signaling pathways.
Conclusions: In addition to providing mechanistic insights, our study revealed that miR-20a-5p and KIF26B contrib-
ute to OS chemoresistance and determined the roles of these genes in this process, which may be critical for charac-
terizing drug responsiveness and overcoming chemoresistance in OS patients.
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Background
Osteosarcoma (OS) is the most common primary bone 
malignancy in children and adolescents, up to 20–25  % 
of diagnosed patients present with metastasis, primar-
ily to the lung [1]. Prior to the use of adjuvant and neo-
adjuvant chemotherapy, the long-term survival rate for 
OS subsequent to surgical resection alone was less than 
20  %. Fortunately, multi-drug chemotherapy regimens 
that were pioneered in the 1970s and early 80s have dra-
matically improved the survival rate, and the necessity 
for chemotherapy treatment for OS patients has been 
demonstrated in randomized controlled trials [2]. Cur-
rently, the standard chemotherapy regimen for newly 
diagnosed OS patients mainly uses cisplatin, doxoru-
bicin, ifosfamide and methotrexate. By combining these 
anti-OS drugs, the 5-year survival rate of patients with 
localized disease has risen to approximately 70  % in 
recent years. However, the outcome remains poor for 
most patients with metastatic or recurrent OS, who have 
less than a 20  % chance of long-term survival despite 
aggressive therapies [3]. To a certain extent, this result is 
likely due to chemoresistance to anti-OS drugs. There-
fore, identifying the mechanisms responsible for regulat-
ing chemotherapy resistance is crucial for improving OS 
treatment. Chemoresistance in tumors occurs by numer-
ous mechanisms, including decreased intracellular drug 
accumulation, drug inactivation, enhanced DNA repair, 
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perturbations in signal transduction pathways, apopto-
sis and autophagy-related chemoresistance, and cancer 
stem cell-mediated drug resistance [4–6]. The regulation 
of post-transcriptional and translational events has been 
well documented to play a key role in tumor chemoresist-
ance [7–12]. MicroRNAs (miRNAs or miRs) can regulate 
translation and play pivotal roles in modulating various 
biological processes, including multi-drug resistance 
in cancer cells. Over 30  % of human protein-encoding 
genes are predicted to be post-transcriptionally regu-
lated by miRs [13–15]. Several studies have shown that 
miRNA misregulation can increase chemoresistance in 
cancer cells if specific proteins are affected [16–18]. For 
instance, miR-33a was found to be upregulated in chem-
oresistant OS and to promote resistance to cisplatin by 
downregulating TWIST [19]. Given the major roles of 
miRNAs in regulating protein expression in general, 
understanding how miRNAs contribute to OS chemore-
sistance is necessary.
In this study, we report that miR-20a-5p was down-
regulated in a multi-drug-resistant (MDR) human OS cell 
line (SJSA-1) and describe the mechanism of OS chem-
oresistance mediated by miR-20a-5p. We provide experi-
mental evidence that miR-20a-5p repression of the direct 
target kinesin family member 26B (KIF26B), a member 
of the kinesin family that can attach to and move along 
microtubules to transport cellular cargoes, improved the 
chemosensitivity of OS cells to multiple drugs, includ-
ing doxorubicin (Dox), etoposide (Etop), methotrexate 
(MTX), cisplatin (CDDP) and carboplatin (Carb). In con-
trast, knockdown of KIF26B increased cellular sensitivity 
to these drugs. More importantly, we found that miR-
20a-5p/KIF26B promoted multi-drug resistance in OS 
cells by regulating MAPK/ERK and cAMP/PKA signal-
ing pathway activities. To the best of our knowledge, this 
study provides the first evidence of the potential utility of 
miR-20a-5p as an important target for developing novel 
OS chemotherapeutics.
Methods
Cell lines and culture
The SJSA-1 (ATCC No. CRL-2098) and G-292 (ATCC 
No. CRL-1423) cell lines were purchased from ATCC. 
Both cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10 % fetal bovine serum (Invitrogen) and 
1 % glutamine at 37 °C in 5 % CO2.
Bisulfite sequencing PCR (BSP) analysis
Genomic DNA was isolated by a standard phenol/chlo-
roform purification method, verified by electropho-
resis on an agarose gel, and treated by an ammonium 
bisulfite-based bisulfite conversion method. Then, the 
PCR fragments from the converted DNA were sequenced 
and analyzed. Raw sequence data files were processed, 
and the area ratio (%) of C over C+T of the primary CpG 
dinucleotide was calculated as the % of methylation and 
plotted [20].
RNA‑seq analysis
RNA-seq analysis was performed by BGI-Tech of 
China, and RNA-seq library preparation and sequenc-
ing were performed by BGI (Shenzhen, China). Follow-
ing purification, RNA was fragmented using divalent 
cations at an elevated temperature, and first-strand 
cDNA was synthesized using random hexamer primers 
and Superscript™ III (Invitrogen, Carlsbad, CA, USA). 
Second-strand cDNA was synthesized using buffer, 
dNTPs, RNase H, and DNA polymerase I. Short frag-
ments were purified with a QIAquick PCR extraction 
kit (Qiagen) and resolved with EB buffer for end repa-
ration and poly (A) addition. The short fragments were 
subsequently connected using sequencing adapters. 
After agarose gel electrophoresis, suitable fragments 
were used as templates for PCR amplification. Dur-
ing the QC steps, an Agilent 2100 Bioanalyzer and an 
ABI StepOnePlus Real-Time PCR System were used in 
quantification and qualification of the sample library. 
Finally, the library (200 bp insert) was sequenced using 
Illumina HiSeq  2000 (Illumina Inc., San Diego, CA, 
USA). The single-end library was prepared following 
the protocol of the Illumina TruSeq RNA Sample Prep-
aration Kit (Illumina) [21].
Transient transfection assays and reagents
Mimic, agomir, antagomir, and scrambled (negative 
control, NC) siRNA sequences as well as a riboFECT 
CP transfection kit were supplied by Guangzhou Ribo-
Bio, China. A GFP-tagged KIF26B overexpression con-
struct (pReciever-M98) was purchased from Genecopia, 
Guangzhou, China (Catalog No.: EX-E0804-M98-5). 
Transfections of the abovementioned ribonucleic acid 
reagents and reporter plasmids were performed accord-
ing to the manufacturer’s instructions. Chemically modi-
fied mimic oligonucleotides (agomir) were synthesized to 
upregulate miR-20a-5p expression in vivo. The 5′ ends of 
the oligonucleotides were conjugated to cholesterol mol-
ecules, and all of the bases were 2′-OMe modified. The 
agomir oligonucleotides were deprotected, desalted and 
purified by high-performance liquid chromatography. 
The siRNA sequences used to produce KIF26B interfer-
ence in this study were as follows:
si-KIF26B:
5′-CGGACAGCCUCUCCUAUUAdTdT-3′
3′-dTdTGCCUGUCGGAGAGGAUAAU-5′
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antagomir: 5′-CUACCUGCACUAUAAGCACUUUA-3′
mimic:
sense 5′-UAAAGUGCUUAUAGUGCAGGUAG-3′
antisense 5′-CUACCUGCACUAUAAGCACUUUA-3′
Luciferase reporter assay
A full-length human KIF26B 3′-untranslated region 
(UTR, 520  bp) and wild-type (WT) and mutant (Mut) 
target sequences for miR-20a-5p were cloned on either 
side of the 3′-region of the luciferase coding sequence 
in the pmiR-RB-REPORT™ vector to construct the 
pmiR-RB-REPORT™-KIF26B vector. The construct was 
confirmed by DNA sequencing. Cells were seeded into 
96-well plates at approximately 1  ×  104 cells per well 
and transfected with a mixture of 50  ng of pmiR-RB-
REPORT™ WT or Mut or of 5  pmol of mimic or NC 
nucleotides using a riboFECT CP transfection kit accord-
ing to the manufacturer’s instructions. Luciferase activity 
was measured 24 h after transfection using a Dual-Lucif-
erase Reporter Assay System (Promega) in tandem with a 
Promega GloMax 20/20 luminometer. The relative firefly 
luciferase activities of the UTR construct and pathway 
reporter constructs were analyzed as previously reported 
[22].
Chemotherapeutics
All of the chemotherapeutic drugs used in this study 
were of clinical grade (NCI Dictionary of Cancer Terms, 
http://www.cancer.gov/dictionary). The following chem-
otherapeutics were used: Dox, doxorubicin (Haizheng, 
Zhejiang, China); Etop, etoposide (Hengrui, Jiangsu, 
China); MTX, methotrexate (Lingnan, Guangdong, 
China); CDDP, cisplatin (Haosen, Jiangsu, China); and 
Carb, carboplatin (Qilu, Shandong, China) [20, 23, 24].
Chemoresistance profiling (IC50 determination)
To perform thiazolyl blue tetrazolium blue (MTT)-based 
cell proliferation assays, experimental groups of cells in 
the logarithmic phase of growth were seeded in triplicate 
in 96-well plates at a cell density of 0.5 ×  104/well and 
treated with fourfold serially diluted drugs for 72 h, after 
which 10  μl (5  mg/ml) of MTT salt (Sigma) was added 
to the corresponding wells. The cells were incubated at 
37 °C for an additional 4 h, and the reaction was stopped 
by lysing the cells with 150 μl of DMSO for 5 min. The 
optical density was measured at 570  nm. A group that 
received no drug treatment was used as a reference for 
calculating the relative cell survival rate.
Apoptosis analysis
Cells were harvested and rinsed twice with phosphate-
buffered saline (PBS). The samples were diluted with 
150  μl of 1×  annexin-binding buffer, and then 5  μl of 
FITC-labeled enhanced-annexin V and 5  μl (20  μg/ml) 
of propidium iodide were added into the cell suspension. 
The cells were incubated in the dark for 15 min at room 
temperature. Flow cytometry was conducted on a FAC-
SCalibur instrument (FACSVerse). The results were ana-
lyzed according to the manufacturer’s instructions. The 
experiments were performed independently three times, 
and the data from a representative experiment are shown.
Cell cycle assay
After transfection with either miR-20a-5p or miR-Ctrl for 
48 h, the cells were collected and fixed in 70 % cold etha-
nol for 24 h at 4 °C. The cells were stained with 50 µg/ml 
propidium iodide (BD Biosciences) at room temperature 
for 30 min in the dark. The cell cycle was evaluated using 
a FACSCalibur instrument (FACSVerse), and the results 
were analyzed according to the manufacturer’s instruc-
tions. All of the experiments were performed indepen-
dently three times, and the data from a representative 
experiment are shown.
RNA analysis
Total RNA was isolated from cells during the logarithmic 
phase using TRIzol (Tiangen Biotech Co., Ltd., Beijing, 
China). For mRNA analysis, a cDNA primed by an oligo-
dT was constructed using a PrimeScript RT reagent kit 
(Tiangen Biotech Co., Ltd., Beijing, China). The KIF26B 
mRNA level was quantified using duplex-qRT-PCR 
analysis, wherein TaqMan probes with a different fluo-
rescence profile were used to detect β-actin (provided 
by Shing Gene, Shanghai, China) in a FTC-3000P PCR 
instrument (Funglyn Biotech Inc., Canada). Using the 
2−ΔΔCt method, target gene expression levels were nor-
malized to the β-actin expression level before the relative 
levels of the target genes were compared. The sequences 
of primers and probes used for the qRT-PCR analysis 
were as follows:
hKIF26B F: 5′-GCTGCGTGTTCTGTTTCGG-3′
hKIF26B R: 5′-TTCCTTGCGTTCGTTTATGAG-3′
hKIF26B probe: 
5′-CY5-TCGGAAAGGATGATTCCATGCAGAAC-3′
hACTB F: 5′-GCCCATCTACGAGGGGTATG-3′
hACTB R: 5′-GAGGTAGTCAGTCAGGTCCCG-3′
hACTB probe: 
5′-HEX-CCCCCATGCCATCCTGCGTC-3′
Bulge‑Loop™ miRNA qRT‑PCR
To detect and quantify the expression of miR-20-5p, 
RNA was reverse-transcribed using a Bulge-Loop™ 
miRNA qRT-PCR Primer Set (RiboBio) and quantified 
using SYBR Green-based real-time PCR analysis in a 
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FTC-3000P instrument (Funglyn Biotech Inc., Canada). 
The Ct values of miR-20-5p were normalized to the Ct 
values of U6 RNA before quantification using the 2−ΔΔCt 
method.
Western blot protein analysis
Cells were lysed with lysis buffer (60 mM Tris–HCl [pH 
6.8], 2  % SDS, 20  % glycerol, 0.25  % bromophenol blue, 
and 1.25  % 2-mercaptoethanol) and heated at 99  °C for 
10 min before electrophoresis/Western blot analysis. The 
primary anti-KIF26B (17422-1-AP) antibodies and anti-
GAPDH (60004-1-lg) antibodies were purchased from 
Proteintech (San Ying Biotechnology, China) and were 
recognized with anti-rabbit IgG peroxidase-conjugated 
antibody (30000-0-AP) (San Ying Biotechnology, China), 
followed by an enhanced chemiluminescence reaction 
(Thermo Fisher Scientific, Waltham, MA, USA). Rela-
tive levels of proteins were quantified using densitometry 
with a Gel-Pro Analyzer (Media Cybernetics, Rockville, 
MD, USA). The target bands over the GAPDH band were 
densitometrically quantified, as indicated under each 
band.
In vivo studies
Animal experiments were performed in accordance with 
the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals. Male BALB/c nude mice 
between 3 and 4 weeks old were used for this study [22]. 
SJSA-1 or G-292 cells were embedded in BD Matrigel 
Matrix (Becton, Dickinson, Franklin Lakes, NJ, USA) 
and subcutaneously injected into two sites on the back 
of each mouse as follows: 1.0 ×  107 cells/site for G-292 
or 4 × 106 cells/site for SJSA-1 into 2 sites/mouse, with 
6 mice in each group. Ten days after cell injection, all of 
the SJSA-1-derived tumors were intratumorally injected 
with 2  nM miR-20a-5p agomir (Ago) every 2  days, 
whereas G-292-derived tumors were injected with 2 nM 
miR-20a-5p/Mock antagomir (Anta)/PBS. Twelve days 
later, after four cell injections, three mice from the G-292 
group and three from the SJSA-1 group intraperitoneally 
received Dox (75  μg/mouse) once every other day. The 
remaining three mice in each group received PBS as a 
mock treatment control. The mice were euthanized on 
day 30 after four drug injections, and their tumors were 
weighed and imaged. Tumor weight was described as 
the mean  ±  S.D. The expression levels of KIF26B and 
Ki67 proteins were measured using immunochemical 
analysis on 5  μm sections of formalin-fixed, paraffin-
embedded tumor xenografts in nude mice. The antigens 
were retrieved by pre-treating the de-waxed sections in 
a microwave oven at 750 Watts for 5 min in citrate buffer 
(pH 6) processed with a Super Sensitive Link-Labeled 
Detection System (Biogenex, Menarini, Florence, Italy), 
and the slides were developed using 3-amino-9-ethyl-
carbazole (Dako, Milan, Italy) as a chromogenic sub-
strate. After the slides were counterstained with Mayer’s 
hematoxylin (Invitrogen), they were mounted in an aque-
ous mounting medium (Glycergel, Dako). Images were 
captured using a Leica DM 4000B microscope (Wetzlar, 
Germany), the relative level of each protein was calcu-
lated using Leica software (Wetzlar, Germany), and the 
percentage of the mock over the chemotherapeutically 
treated tumors was calculated and plotted.
Statistical analysis
All of the results are represented as the mean ±  stand-
ard deviation (SD) of three independent experiments. 
Two-tailed Student’s t test, one-way analysis of variance 
or Mann–Whitney U test was used to calculate statisti-
cal significance. All of the statistical analyses were per-
formed with Microsoft Excel 2010 (Microsoft, Redmond, 
WA). A p value of less than 0.05 was designated statisti-
cally significant.
Results
Expression of the DNA methylation‑regulated miR‑20a 
gene positively correlates with the multi‑chemoresistance 
of OS cells
The doses at which 50 % of cells were killed by the drugs 
Dox, Etop, MTX, CDDP and Carb following individual 
72 h treatments were determined in the following seven 
OS cell lines: G-292, SJSA-1, MG63.2, MG63, Saos.2, 
U2OS, and MNNG/HOS. Evaluating the fold difference 
over the lowest IC50 value, G-292 was the most multi-
chemosensitive cell line, with the lowest IC50 values for 
three of five drugs, whereas the SJSA-1 cell line was the 
most multi-chemoresistant cell line, with a relative IC50 
that was 27.11-fold higher than that of G-292 cells [25]. 
To profile miRNA expression in the G-292 and SJSA-1 
OS cell lines, we performed RNA-seq-based miR-omic 
analysis and referred to the relevant literature, and miR-
20a-5p was selected as one of the studied target genes. 
The RT-PCR validation also confirmed that miR-20a-5p 
was significantly more highly expressed in the G-292 
than the SJSA-1 cell line (by more than eightfold), sug-
gesting that this miR might be involved in regulating the 
multi-drug resistance of OS cells.
To investigate the epigenetic regulation of miR-20a-5p 
expression, the methylation status of the miR-20a pro-
moter region was assessed in both the SJSA-1 and G-292 
cell lines using the bisulfite sequencing PCR (BSP) assay. A 
total of 15 CpG sites in this region were methylated at vary-
ing ratios (Fig. 1a, b). The methylation ratio of the miR-20a 
gene in SJSA-1 cells in most CpG islands is much higher 
than the ratio in G-292 cells, as high as approximately 
10-fold on average (51.53:5.67, Fig.  1c, d), indicating that 
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miR-20a methylation is negatively correlated with miR-
20a-5p expression (Fig. 2a, b). In conclusion, both the DNA 
methylation and gene expression levels of miR-20a-5p are 
tightly correlated with multi-drug resistance in OS cells.
MiR‑20a‑5p specifically suppresses KIF26B expression 
in OS cells
To examine the effects of miR-20a-5p on the expression of 
its targets in OS, we measured the RNA and protein lev-
els of putative miR-20a-5p target genes, which were cho-
sen by TargetScan (http://www.targetscan.org/). Among 
these genes, the expression of kinesin family member 26B 
(KIF26B), which has a binding site for miR-20a-5p in the 
3′-UTR of its mRNA, was opposite to that of miR-20a-5p 
at both the RNA (Fig. 2c, d) and protein levels (Fig. 2e) in 
G-292 and SJSA-1 cells. Furthermore, to assess whether 
miR-20a-5p directly alters the expression of KIF26B in the 
above OS cell lines, we measured KIF26B levels in OS cell 
lines that were transfected with either a miR-20a-5p mimic 
(SJSA-1) or an antagomir (G-292). Western blot results 
showed that KIF26B expression was suppressed by trans-
fection of the miR-20a-5p mimic in SJSA-1 cells (~28 %) 
and enhanced in antagomir-transfected G-292 cells 
(~3.15-fold) (Fig. 3a–e) relative to the negative control.
Fig. 1 Differential methylation of the miR-20a gene in SJSA-1 cells compared with G-292 cells. a BSP primers and CpG dinucleotides of miR-20a are 
shown. b Original sequencing results of both strands of the PCR product from the bisulfite-converted DNA. c Relative methylation levels (fold) of 
miR-20a in SJSA-1 and G-292 cells. d Methylation percentage at each CpG site in the SJSA-1 and G-292 cells
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To confirm KIF26B as a real miR-20a-5p target, the WT 
or Mut 3′-UTR region (520 bp) of KIF26B was inserted 
downstream of the luciferase gene in the pmiR-RB-
REPORT™ vector (Guangzhou RiboBio, China) to create 
the pmiR-RB-REPORT™-UTR WT and Mut, respectively 
(Fig.  3f ), and assayed in SJSA-1 and G-292 cell lines to 
determine the functional status of miR-20a-5p in OS 
cells. Transfection of pmiR-RB-REPORT-UTR WT, but 
not of the other two reporter constructs, resulted in sig-
nificantly higher luciferase activity in SJSA-1 cells than in 
G292 cells. Furthermore, the luciferase activity of pmiR-
RB-REPORT-UTR WT, but not of the other two con-
structs, was decreased by the mimic in SJSA-1 cells and 
increased by the antagomiR in G292 cells (Fig. 3). In con-
clusion, the KIF26B gene was shown to be a novel direct 
target of miR-20a-5p in OS cells and might contribute to 
miR-20a-5p-mediated multi-drug resistance in OS cells.
Overexpression of KIF26B modulates multi‑drug resistance 
effects similar to miR‑20a‑5p knockdown in OS cells
To further demonstrate that miR-20a-5p modulates 
multi-drug resistance by repressing KIF26B expression 
in OS cells, we compared drug-triggered cell death in 
SJSA-1 cells transfected with miR-20a-5p mimic or 
KIF26B siRNA. The results showed that transfection with 
the miR-20a-5p mimic reduced the KIF26B level to 36 % 
of that found in the NC and that KIF26B siRNA inhib-
ited KIF26B protein expression to approximately 40 % of 
the NC control (Fig. 4a). The transfection of mimic and 
KIF26B siRNA into SJSA-1 cells induced drug-triggered 
death, except for the transfection of the mimic to CDDP 
(Fig. 4b). In contrast, antagomir transfection and KIF26B 
overexpression repressed cell death in SJSA-1 cells 
stressed by Dox, Etop, CDDP and Carb, but not in cells 
stressed by MTX (Fig. 4c, d). This discrepancy suggested 
that KIF26B might not mediate OS chemoresistance in 
response to MTX.
Additionally, the miR-20a-5p mimic mediated KIF26B 
downregulation in SJSA-1 cells and increased the per-
centage of apoptotic cells from 1.29 to 5.01 %. Similarly, 
knockdown of KIF26B with siRNA also elevated the 
apoptotic ratio of SJSA-1 cells (Fig.  5a, b). This result 
indicated that low levels of miR-20a-5p promoted OS 
cell survival probably by increasing KIF26B expression. 
Fig. 2 Different expression patterns of miR-20a-5p/KIF26B in SJSA-1 and G-292 cells. The miR-20a-5p expression levels in SJSA-1 cells compared 
with G-292 cells (summarized in Table a) were analyzed by miR-seq and qRT-PCR analyses in plot b. The expression level of KIF26B is higher in SJSA-1 
cells than in G-292 cells, as summarized in Table c. Western blot and qRT-PCR analyses are shown in plots d and e, respectively
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Furthermore, FACS analysis of the cell cycle in SJSA-1 
cells showed that the percentage of S stage cells signifi-
cantly decreased after miR-20a-5p mimic transfection 
or KIF26B knockdown (Fig.  5c, d). This result implies 
that KIF26B could play a role in arresting cells to facili-
tate the necessary repair of cellular damage induced by 
stress, such as by anti-cancer drugs. All of these observa-
tions suggest that KIF26B acts as a downstream target of 
miR-20a-5p and mediates chemoresistance against Dox, 
Etop, MTX, CDDP and Carb in OS cells.
MiR‑20a‑5p and KIF26B regulate the activities 
of chemoresistance‑associated signaling pathways 
in multi‑drug resistant OS cells
To further explore the mechanism underlying OS chem-
oresistance, we detected the activities of the following 
Fig. 3 KIF26B is a direct target of miR-20a-5p in OS cells. Expression levels of miR-20a-5p (a, b) and KIF26B mRNA (d, e) and protein (c) in miR-
20a-5p mimic (5PM)-transfected SJSA-1 cells and miR-20a-5p antagomir (5PA)-transfected G-292 cells compared with the negative control (NC) as 
determined by qRT-PCR and Western blot analyses. f Layout of the luciferase reporter plasmid and the sequence of the WT and Mut UTR region of 
the KIF26B gene targeted by miR-20a-5p. g–i, The relative luciferase activity (fold change) of the reporter with WT or Mut KIF26B-UTR or with no 
UTR (Vec) was determined in the miR-20a-5p mimic (in SJSA-1)- or antagomir (in G292)- or Mock-transfected cells. Renilla luciferase activity of a co-
transfected control plasmid was used as a transfection efficacy control. Representative results from three independent experiments are shown. Error 
bars represent the s.e.m. **p < 0.01 by Student’s t-test
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seventeen signaling pathways using Qiagen pathway 
reporter systems in both SJSA-1 and G-292 cells: oxida-
tive stress, DNA damage, NF-κB, hypoxia, ER stress, heavy 
metal stress, heat shock, glucocorticoid, JNK, xenobiotic, 
Wnt, Notch, TGF-β, cell cycle/pRb-E2F, Myc/Max, and 
MAPK/ERK (Fig. 6a). The activities of six of the signaling 
Fig. 4 Effects of forced alteration of miR-20a-5p or KIF26B expression on chemoresistance in SJSA-1 and G-292 cells. a KIF26B protein levels in 5PM- 
or siRNA-transfected SJSA-1 cells compared with the NC. b Cell survival rate after administering IC50 doses of drugs to SJSA-1 cells transfected with 
miR-20a-5p mimic (3PM) or KIF26B siRNA relative to the negative control (NC). c Levels of KIF26B protein in GFP-KIF26B-transfected cells compared 
with GFP control-transfected G-292 cells. d Relative cell survival rates after transfections with miR-20a-5p antagomir (5PA), GFP, or GFP-KIF26B com-
pared with transfection with the NC in G-292 cells treated with IC50 doses of drugs. e (*p < 0.05; **p < 0.01)
Fig. 5 Effects of forced alteration of miR-20a-5p or KIF26B levels on the cell survival of SJSA-1 cells. a, b The effects of forced expression of miR-
20a-5p and knockdown of KIF26B on the apoptosis of SJSA-1 cells shown by FACS analysis in table and in the original. c, d The effects of the forced 
expression of miR-20a-5p or knockdown of KIF26B on the cell cycle distribution of SJSA-1 cells shown by FACS analysis in plot and in the original
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pathways, i.e., p53/DNA damage, NF-κB, MAPK/ERK, 
ATF2/ATF3/ATF4, cAMP/PKA and MEF2 pathways, dif-
fered by more than twofold between the two OS cell types, 
suggesting that these pathways might be involved in OS 
chemoresistance. The pathways with higher activity in 
SJSA-1 cells compared with G-292 cells were the p53/DNA 
damage and NF-κB pathways, whereas the other four path-
ways showed lower activity in SJSA-1 cells compared with 
Fig. 6 Signaling pathways regulated by miR-20a-5p and KIF26B. a Experimental scheme. b Relative activities (mean ± S.D) of the 6 pathways 
that differed by more than twofold between SJSA-1 and G-292 cells. c Relative activities of the 6 pathways regulated by miR-20a-5p in OS cells. d 
Relative activities of the 6 pathways regulated by KIF26B in G-292 and SJSA-1 cells. The boxes indicate the pathways that failed to respond in an 
expected manner
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G-292 cells. Furthermore, of these six pathways, MAPK/
ERK, ATF2/ATF3/ATF4, and cAMP/PKA signaling path-
way activity increased in miR-20a-5p mimic-transfected 
SJSA-1 cells and decreased in antagomir-transfected 
G-292 cells (Fig.  6b, c). We also knocked down KIF26B 
expression in SJSA-1 cells by siRNA transfection and over-
expressed KIF26B in G-292 cells by GFP-KIF26B trans-
fection to determine its effects on these pathways. We 
observed activity changes only in the NF-κB, MAPK/ERK 
and cAMP/PKA pathways, which was in accordance with 
the differences observed between SJSA-1 and G-292 cells 
(Fig.  6d). Combining the results from all of these assays, 
the MAPK/ERK and cAMP/PKA signaling pathways were 
most likely to contribute to OS chemoresistance mediated 
by the miR-20a-5p/KIF26B axis.
KIF26B expression decreases in miR‑20a‑5p 
agomiR‑injected SJSA‑1 tumor xenografts and increases 
in antagomir‑injected G‑292 tumor xenografts in nude 
mice
Intratumoral injection of miR-20a-5p agomir/antagomir 
or the scramble sequence control (Mock) or PBS into 
SJSA-1/G-292-derived tumors was initiated on the tenth 
day and repeated four times once every 2  days. Then, 
intraperitoneal injection of PBS or Dox was initiated in 
the G-292 and SJSA-1 groups and repeated four times, 
once every 2 days (Fig. 7a). In the SJSA-1 tumor mice that 
received intratumoral injection of miR-20a-5p agomir, 
the mock tumor xenograft was lighter than the Ago-5P 
tumor xenograft. The reverse effect was observed for the 
antagomir in G-292 tumor mice. Therefore, miR-20a-5p 
is capable of inhibiting in  vivo tumor growth. Consist-
ent with the observation that cultured SJSA-1 cells were 
more resistant to Dox than cultured G-292 cells, intra-
peritoneal injection of Dox resulted in larger G-292 
tumors than SJSA-1 tumors (Fig.  7b–f). Furthermore, 
the tumor weight of the miR-20a-5p agomir/Dox injected 
SJSA-1 mice was smaller than that in the miR-20aa-5p 
agomir/Mock counterparts, and the reverse observa-
tion was found in that of Dox-treated group of G-292 
cells with and without miR-20a-5p agomir transfection 
(Fig. 7b–f). These results indicated that miR-20a-5p com-
promised the tumor-inhibition capability of Dox.
Further confirmation of the role of miR-20a-5p in OS 
cell resistance to Dox was obtained by immuno-histo-
logical analysis of KIF26B and Ki67 in tumor sections of 
Dox-treated versus PBS-treated mice. Intratumoral injec-
tion of the miR-20a-5p agomir/antagomir indeed led to 
the expected changes in KIF26B levels in tumor sections 
(Fig. 7g), which confirmed that miR-20a-5p has a profound 
negative effect on both the growth and chemoresistance of 
the OS cell-derived tumor xenografts in nude mice.
Discussion
OS chemoresistance is an important topic in the design 
of clinical treatment protocols because this resistance 
contributes to relapse and poor prognosis. In this study, 
we demonstrated that the expression level of miR-20a-5p 
varies in OS cells with different levels of chemosensitivity, 
suggesting that miR-20a-5p might participate in the reg-
ulation of OS chemoresistance. miR-20a-5p expression 
has been shown to correlate with the development and 
progression of diverse cancer types [26–36]; for exam-
ple, miR-20a-5p can be downregulated by glioblastoma 
hypoxia [31], which often promotes radioresistance and 
chemoresistance in cancer cells. However, knowledge of 
the contribution of miR-20a-5p to OS chemoresistance is 
still limited. In this investigation, we tested the impact of 
differential expression of miR-20a-5p on cell death in OS 
cells triggered by commonly used therapeutics.
To explore how miR-20a-5p affects chemoresist-
ance regulation in OS, a luciferase reporter assay was 
performed to identify potential target genes of miR-
20a-5p. The results showed that miR-20a-5p directly tar-
geted kinesin family member 26B (KIF26B) in OS cells. 
Numerous studies have shown that abnormal expression 
and function of kinesins play key roles in the develop-
ment and progression of many human cancers [37, 38]. 
KIF26B consists of 2108 amino acids and has a pre-
dicted molecular weight of 223.8 kDa. In mice, KIF26B 
plays a role in embryogenesis, specifically in the devel-
opment of limbs, faces, and somites [39]. KIF26B also 
plays an important role in kidney development and is 
involved in the development and progression of certain 
types of tumors, including breast cancer, esophageal 
adenocarcinoma, and colorectal adenomatous poly-
posis [40–44]. Although studies of KIF26B effects with 
respect to tumor chemoresistance are rare, several stud-
ies have shown that overexpression of other kinesins 
might promote chemoresistance [45–51]. For example, 
a recent study demonstrated that KIF14 contributes to 
chemoresistance in breast cancer by promoting AKT 
phosphorylation [50], and other research has shown that 
overexpression of kinesins (including KIFC3, KIFC1, 
KIF1A and KIF5A) mediates docetaxel resistance in 
breast cancer cells [47]. The current study is the first to 
demonstrate that KIF26B mRNA and protein expression 
is upregulated in OS cells because of hypermethylation 
of its upstream regulator miR-20a. We further demon-
strated that KIF26B overexpression promotes multi-
drug resistance in OS cells.
Given that kinesins are involved in mitosis, KIFs have 
attracted significant attention in the search for novel and 
alternative mitotic drug targets to treat cancer [52–54]. 
Several KIF11 inhibitors have entered Phase I or Phase 
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Fig. 7 The effect of miR-20a-5p on both the in vivo growth and Dox chemoresistance of SJSA-1- and G-292-derived xenografts in nude mice. a 
The experimental scheme. SJSA-1 or G-292 cells were subcutaneously injected at two sites on the back of each nude mouse. Two sites/mouse, 6 
mice for SJSA-1, and 6 mice for G-292. From the tenth day after cell injection, all six SJSA-1-generated tumors on the left side of the backs of the 
nude mice were intratumorally injected with 2 nM miR-20a-5p agomir, while the right side of their backs was injected with 2 nM Mock. G-292-gen-
erated tumors on the left side of the backs of the nude mice were injected with 2 nM miR-20a-5p antagomir, while the right side of their backs 
was injected with 2 nM Mock. After cell injection, 3 mice from SJSA-1 and 3 from G-292 were intraperitoneally injected with Dox (45 µg/mouse) 
once every 2 days for 4 times. The remaining 6 mice (3 from SJSA-1 and 3 from G-292) received PBS as a mock treatment control. b Image of the 
representative mice with tumors. The mean ± SD of tumor weight of the tumors from the same treatment was calculated, plotted (*p < 0.05), and 
summarized in c–f. g Levels of KIF26B in each group were determined by immunostaining and summarized in the Table (Magnification: 200×)
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II clinical trials, either in combination with other drugs 
or as monotherapies [37]. Vaccination with a KIF20A-
derived peptide in combination with gemcitabine is a 
feasible and promising approach for the treatment of 
advanced pancreatic cancer [55]. We hypothesized that 
knockdown of KIF26B would reduce cancer cell prolif-
eration and is therefore a potential therapeutic target. 
In this study, we showed that KIF26B knockdown in OS 
cells promoted cell death. In addition, exogenous expres-
sion of KIF26B significantly inhibited the cell death 
induced by multiple drugs. These data indicate that sup-
pression of KIF26B inhibits cell survival and implicate 
KIF26B as a potential therapeutic target for OS.
To obtain further mechanistic understanding, we used 
GeneMANIA to search for interactions between KIF26B 
and the master transcription factor genes involved in 
the MAPK/ERK and cAMP/PKA signaling pathways 
(Fig. 8); we determined that KIF26B interacts with SRF 
and CREB. These proteins are likely involved in KIF26B-
mediated OS chemoresistance, especially the protein 
MYH10, which physically interacts with KIF26B and 
GATA6, a co-expresser of KIF26B (Fig.  8). Myosin X 
(MYO10), which is encoded by the MYH10 gene and 
which acts as a molecular motor located at the tips of 
filopodia, is essential for many cell processes, including 
wound healing [56], filopodial formation [57], angiogen-
esis [58], growth cone formation and turning regulation 
[59], and invadopodia formation [60]. Recently, MYO10 
was reported to be overexpressed in breast cancer and to 
promote invasive growth [61, 62]. GATA6 is a member 
of the highly conserved GATA family, which contains 
six zinc-finger transcription factors that regulate line-
age-restricted development, differentiation, and cellular 
aging [63–65]. GATA6 has been reported to be overex-
pressed in several tumors. For example, 18q11.2 gain/
amplification with overexpression of GATA6 is detected 
in 9–19 % of pancreatic carcinomas [66, 67]. GATA6 is 
highly expressed in gastric, colonic, pancreatic, pulmo-
nary, and prostatic cancer cell lines [68–70]. Moreover, 
GATA6 can promote cell survival by inhibiting apoptosis 
[71–74]. Therefore, GATA6 likely contributes to chem-
oresistance. Moreover, other KIF26B-associated proteins 
(e.g., MAP4K4, NF-κB, CREB, REL, PRKACA, and SRF) 
have been demonstrated to contribute to chemoresist-
ance in previous studies. Therefore, induction of chem-
oresistance by KIF26B-regulated protein interaction 
networks in the MAPK/ERK and cAMP/PKA pathways 
is possible.
In summary, we demonstrated that a miR-20a-5p-cen-
tered axis dictates OS multi-chemoresistance. Expression 
of the miR-20a gene was negatively controlled by DNA 
methylation. Because of its repressive effect on KIF26B 
and other downstream effects on two signaling pathways, 
decreasing miR-20a-5p expression promotes OS multi-
drug resistance (at least for Dox, Etop and Carb, which 
were studied in this report) both in  vitro and in  vivo. 
Moreover, we bioinformatically identified key links that 
connect miR-20a-5p to two signaling pathways via its tar-
get gene KIF26B, through which a chemoresistant pheno-
type is produced in OS cells. Our data suggested that the 
miR-20a-5p level might serve as a potential biomarker of 
chemotherapy-resistant OS and that miR-20a-5p overex-
pression might aid in overcoming OS drug resistance.
Conclusion
In conclusion, this study is the first to illustrate that miR-
20a-5p can regulate OS multi-drug resistance through 
its direct target gene KIF26B by targeting it in a classical 
3′-UTR binding fashion. Our findings suggest that miR-
20a-5p may function as a potential biological molecule 
for preventing chemoresistance of OS, which may lead 
to additional new diagnostic and therapeutic approaches 
for OS and provide new insights into the posttranscrip-
tional regulation of KIF26B. Indeed, other regulators of 
KIF26B may also participate in OS chemoresistance, and 
our future studies should pay greater attention to exam-
ining how KIF26B is regulated in OS or other human 
tumors.
Fig. 8 A simplified interaction map between the target gene 
(KIF26B) and the TGFβ, Myc/Max and ATF2/ATF3/ATF4 pathways was 
generated using GeneMANIA (http://www.genemania.org/). Orange 
nodes represent the proposed genes. Gray nodes represent genes 
related to the proposed genes by GeneMANIA. Web-based interface 
searching provided a large set of functional association data to return 
related genes based on available genomic and proteomic data. The 
association data include protein, DNA and genetic interactions and 
pathways; gene and protein expression data; phenotypic screens and 
shared protein domains
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